Pharvaris is a Nasdaq listed late-stage biotech company developing bradykinin B2 receptor antagonists for bradykinin-mediated diseases, with offices in Switzerland (Zug), the Netherlands (Leiden) and the U.S.A. (greater Boston area).

We aim at bringing new, more convenient options to Hereditary Angioedema ( HAE) patients who suffer sudden and prolonged attacks of swelling in multiple areas of the body including the airway, which can be life-threatening.

We have a culture built on the core values of considering others carefully, leading with trust, ensuring rigor and diversity of thought, and contributing freely.

Our company is driven by individuals committed to developing breakthrough therapies which can have a real impact on people’s lives.

If you are looking for a place where your work can have meaning, and you can make a difference – Pharvaris is the place for you!

As we are expanding the U.S.

Commercial team...